Latest market price
51.22
+0.41+0.81%
Earnings
Up 0.8% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 133.71 | EPS (ttm) | 0.38 | Insider Own | 42.69% | Shs Outstand | 28.58M | Perf Week | 1.28% |
| Market Cap | 1.45B | Forward P/E | 24.38 | EPS next Y | 2.08 | Insider Trans | -5.18% | Shs Float | 22.30M | Perf Month | -8.22% |
| Enterprise Value | 1.45B | PEG | 2.27 | EPS next Q | 0.31 | Short Float | 8.72% | Perf Quarter | 10.87% | ||
| Income | 13.00M | P/S | 13.83 | EPS this Y | 193.75% | Short Ratio | 3.23 | Perf Half Y | 68.47% | ||
| Sales | 105.00M | P/B | 30.90 | EPS next Y | 91.79% | ROA | 10.96% | Short Interest | 1.94M | Perf YTD | 200.47% |
| Book/sh | 1.64 | P/C | 53.79 | EPS next 5Y | 58.98% | ROE | 40.13% | 52W High | 66.37 -22.83% | Perf Year | 178.41% |
| Cash/sh | 0.94 | P/FCF | 103.74 | EPS past 3/5Y | — | ROIC | 20.41% | 52W Low | 14.27 258.93% | Perf 3Y | 1223.18% |
| Dividend Est. | — | EV/EBITDA | 72.72 | Sales past 3/5Y | 56.18% — | Gross Margin | 57.87% | Volatility | 4.45% 4.62% | Perf 5Y | 820.47% |
| Dividend TTM | — | EV/Sales | 13.85 | EPS Y/Y TTM | — | Oper. Margin | 15.44% | ATR (14) | 2.66 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.30 | Sales Y/Y TTM | 81.03% | Profit Margin | 12.02% | RSI (14) | 43.74 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.52 | EPS Q/Q | 450.00% | SMA20 | -2.40% | Beta | 0.84 | Target Price | 72.00 |
| Payout | 0.00% | Debt/Eq | 0.62 | Sales Q/Q | 100.00% | SMA50 | -8.86% | Rel Volume | 0.98 | Prev Close | 50.81 |
| Employees | 44 | LT Debt/Eq | 0.43 | Earnings | Nov 05 | SMA200 | 41.60% | Avg Volume | 567.95K | Price | 51.22 |
| IPO Date | Nov 14, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 84.40% 38.67% | Net Debt/EBITDA | 0.10 | Volume | 557,104 | Change | 0.81% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-15-26 | Reiterated | Craig-Hallum | Buy | $76 → $78 |
| Aug-14-26 | Reiterated | Canaccord Genuity | Buy | $60 → $68 |
| Aug-14-26 | Reiterated | HC Wainwright & Co. | Buy | $65 → $70 |
| Aug-11-26 | Reiterated | HC Wainwright & Co. | Buy | $57 → $65 |
| Jul-28-26 | Reiterated | Craig-Hallum | Buy | $15 → $62 |
| Jul-16-26 | Initiated | Canaccord | Buy | $60 |
| May-15-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $57 |
| May-29-25 | Reiterated | HC Wainwright & Co. | Buy | $11 → $35 |
| Oct-28-24 | Reiterated | Craig-Hallum | Buy | $8.00 → $15 |
| Oct-04-24 | Reiterated | HC Wainwright & Co. | Buy | $9.00 → $11 |
Latest News· Times ET
Nov-02-26
06:50AM
Oct-29-26
Oct-29-2606:50AM
Oct-26-26
Oct-26-2604:57AM
Oct-22-26
Oct-22-2603:13PM
Oct-14-26
Oct-14-2606:50AM
Oct-08-26
Oct-08-2604:15AM
Oct-07-26
Sep-30-26
Sep-30-2604:30AM
Sep-28-26
Sep-28-2606:50AM
03:29AM
Sep-02-26
Sep-02-2603:50AM
Sep-01-26
Sep-01-2607:01AM
Company
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 105 | 80 | 39 | 32 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 45 | 37 | 16 | 11 | — | — | — | — | — | |
| Gross Profit | 61 | 43 | 23 | 21 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 39 | 36 | 23 | 19 | — | — | — | — | — | |
| Research and Development | 6 | 8 | 3 | 3 | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 16 | 0 | -3 | -1 | — | — | — | — | — | |
| Interest Expense | 2 | 5 | 2 | 1 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | 0 | 1 | 2 | — | — | — | — | — | |
| Net Income Before Taxes | 13 | -5 | -4 | -1 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 13 | -5 | -4 | -1 | — | — | — | — | — | |
| Net Income From Continuing Operations | 13 | -5 | -4 | -1 | — | — | — | — | — | |
| Net Income | 13 | -5 | -4 | -1 | — | — | — | — | — | |
| EPS (Recurring) | 0.47 | -0.17 | -0.15 | -0.04 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.47 | -0.17 | -0.15 | -0.04 | — | — | — | — | — | |
| EPS (Diluted) | 0.38 | -0.17 | -0.15 | -0.04 | — | — | — | — | — | |
| EBITDA | 20 | 4 | -1 | 0 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 134.79 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.66 | 5.71 | 8.88 | 3.56 | — | — | — | — | — | |
| Gross Margin | 58.10 | 53.75 | 58.97 | 65.63 | — | — | — | — | — | |
| Operating Margin | 15.24 | 0.00 | -7.69 | -3.13 | — | — | — | — | — | |
| Net Margin | 12.38 | -6.25 | -10.26 | -3.13 | — | — | — | — | — | |
| Shares Outstanding | 28 | 27 | 26 | 26 | — | — | — | — | — | |
| Market Capitalization | 1,434 | 457 | 346 | 114 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Krempa David | Chief Business Officer | Oct 06 '26 | Sale | 55.07 | 4,166 | 229,406 | 43,381 | Oct 06 |
| Krempa David | Chief Business Officer | Oct 02 '26 | Option Exercise | 0.00 | 10,522 | 0 | 47,547 | Oct 06 |
| MAIER PAUL V | Director | Aug 28 '26 | Option Exercise | 4.96 | 75,000 | 371,750 | 109,745 | Aug 31 |
| MAIER PAUL V | Director | Aug 28 '26 | Sale | 59.07 | 50,000 | 2,953,573 | 59,745 | Aug 28 |
| Krempa David | Chief Business Officer | Aug 24 '26 | Option Exercise | 7.31 | 25,000 | 182,750 | 62,025 | Aug 24 |
| Krempa David | Chief Business Officer | Aug 24 '26 | Sale | 65.07 | 25,000 | 1,626,750 | 37,025 | Aug 24 |
| BRYNJELSEN SEAN | President & CEO | Aug 20 '26 | Sale | 60.70 | 91,022 | 5,525,301 | 961,194 | Aug 20 |
| BRYNJELSEN SEAN | President & CEO | Aug 19 '26 | Sale | 62.65 | 8,978 | 562,472 | 1,052,216 | Aug 20 |
| Opaleye Management Inc. | 10% Owner | Jul 14 '26 | Sale | 37.54 | 56,630 | 2,126,066 | 40,000 | Jul 17 |
| BRYNJELSEN SEAN | President & CEO | Jul 14 '26 | Option Exercise | 1.37 | 400,000 | 548,000 | 1,061,194 | Jul 14 |
| BRYNJELSEN SEAN | President & CEO | Jul 12 '26 | Option Exercise | 0.00 | 27,500 | 0 | 861,194 | Jul 14 |
| Krempa David | Chief Business Officer | Jul 12 '26 | Option Exercise | 0.00 | 10,000 | 0 | 37,025 | Jul 13 |
| Opaleye Management Inc. | 10% Owner | Jul 07 '26 | Sale | 38.37 | 26,685 | 1,023,978 | 53,315 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 06 '26 | Sale | 38.00 | 10,000 | 380,000 | 2,700,000 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 02 '26 | Sale | 37.39 | 90,000 | 3,364,660 | 60,000 | Jul 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.